當前位置：   首頁(yè) > 需求大廳

 >  生產(chǎn)研發(fā) 

 >  藥理毒理 

單人中標 賞金分配： $ 15000 截止日期：2014年12月4日 已有提案：75件 發(fā)布時(shí)間：2014年11月4日 已選0個(gè)，還需要1個(gè)。 具體要求： 研究人員想要一種小分子拮抗劑NK 3（神經(jīng)激肽受體3，也被稱(chēng)為速激肽受體3）新的臨床適應癥。許多中樞神經(jīng)系統的臨床適應癥NK3拮抗劑已經(jīng)被考慮，如精神分裂癥的治療和藥物成癮的治療。研究人員對NK3拮抗劑可以忍受的適應癥，或其已知的藥理作用特別感興趣。最近的研究表明，有一種隨著(zhù)NK-3拮抗劑作用而降低的性激素的適應癥。這一懸賞只需要一個(gè)書(shū)面建議。 以下幾條信息必須同時(shí)滿(mǎn)足: 1. 必須在2014年12月4日下午11時(shí)59分（美國東部時(shí)間）收到，逾期的投標概不受理。只需要提案人一個(gè)書(shū)面建議提交。解決方領(lǐng)取獎金的同時(shí)，必須將其獨有的知識產(chǎn)權（IP）的權利轉讓給舉辦方。 2.這個(gè)懸賞任務(wù)是必須尋找一種小分子拮抗劑NK 3（神經(jīng)激肽受體3，也被稱(chēng)為速激肽受體3）新的臨床適應癥 3、在這個(gè)網(wǎng)站上投稿：New Disease Indications for NK3 (Tachykinin Receptor 3) Antagonists | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933526   [更多]

截止日期：2015年1月6日 已有提案：8件 發(fā)布時(shí)間：14年11月20日 已選0個(gè)，還需要1個(gè)。 具體要求：雙特異性抗體（BsAbs）在效力上優(yōu)于常規的單克隆抗體（mAb），因為它們一定擁有兩個(gè)特定的藥理潛在優(yōu)勢。這可能導致比由或單一的單克隆抗體或甚至單抗聯(lián)合治療能夠取得更大的效力。葛蘭素史克對這一新興的生物制藥領(lǐng)域有著(zhù)濃厚的興趣，并取得了許多實(shí)驗進(jìn)展，比如從BsAb分子到臨床實(shí)驗研究。對于某些BsAb配對，我們也看到，雙特異性抗體和單克隆抗體結合方法上的標準有所不同。 雖然對BsAb使用公認的最好的醫療應用是在控制T細胞活化方面，葛蘭素史克公司對直接控制抗體方面也有興趣，比如方便配體/受體靶對的抑制或激活的研究。 這一懸賞只需要一個(gè)書(shū)面建議。 以下幾條信息必須同時(shí)滿(mǎn)足: 1. 必須在2015年1月6日下午11時(shí)59分（美國東部時(shí)間）收到，逾期的投標概不受理。只需要提案人一個(gè)書(shū)面建議提交。解決方領(lǐng)取獎金的同時(shí)，必須將其獨有的知識產(chǎn)權（IP）的權利轉讓給舉辦方。 2.這個(gè)懸賞任務(wù)是必須尋找一種雙特異性抗體識別機制來(lái)預測任何給定目標抗體的配對及協(xié)同作用能力。葛蘭素史克因此熱情邀請更廣泛的研發(fā)人員，創(chuàng )建出這種方法，讓雙特異性抗體比等效單抗的聯(lián)合治療更有效。 3、投稿在此網(wǎng)站：https://www.innocentive.com/ar/challenge/9933655   [更多]

單人中標 賞金分配： $ 50,000 截止日期：計2015年1月12日 已有提案：57 件 發(fā)布時(shí)間：2014年11月6日 已選0個(gè)，還需要1個(gè)。 具體要求： 與年齡相關(guān)的黃斑變性（AMD）是造成50歲以上人的視力喪失的主要原因。黃斑變性會(huì )造成視網(wǎng)膜的中央點(diǎn)損害，并模糊，最后會(huì )使一個(gè)或兩個(gè)眼睛發(fā)展到失明。雖然AMD已有少量模型存在，但并沒(méi)有充分闡明疾病的病理，而且也不適合于徹底深入地篩選和開(kāi)發(fā)藥物。年齡相關(guān)性黃斑變性（AMD）被認為是由遺傳和環(huán)境因素來(lái)觸發(fā)一種復雜而且異質(zhì)性疾病。正如它的名字所示的，隨著(zhù)年齡的增長(cháng)AMD發(fā)病率增加，據估計，在美國，大約有800萬(wàn)55周歲以上的人具有中期或后期的疾病。 AMD出現的第一癥狀為黃斑色素的改變和被稱(chēng)為玻璃疣的視網(wǎng)膜下沉積物。疾病進(jìn)一步發(fā)展可能導致視網(wǎng)膜色素上皮（RPE）細胞和光感受器細胞或新血管的血管滲透，出血和疤痕。光感受器細胞和視網(wǎng)膜色素上皮細胞之間的相互作用對于正常的視力功能是必不可少的。這一懸賞只需要一個(gè)書(shū)面建議。 以下幾條信息必須同時(shí)滿(mǎn)足: 1. 必須在2015年1月12日下午11時(shí)59分（美國東部時(shí)間）收到，逾期的投標概不受理。只需要提案人一個(gè)書(shū)面建議提交。解決方領(lǐng)取獎金的同時(shí)，必須將其獨有的知識產(chǎn)權（IP）的權利轉讓給舉辦方。 2.這個(gè)懸賞任務(wù)是必須尋找一種新的，臨床前模型，描述光感受器細胞和視網(wǎng)膜色素上皮細胞之間的相互作用，在長(cháng)期生理分化中對視力的影響，以方便對最近出現的新興療法進(jìn)行療效評價(jià)。 3、在這個(gè)網(wǎng)站投稿：Preclinical Models of Age-Related Macular Degeneration | InnoCentive Challenge https://www.innocentive.com/ar/challenge/9933641   [更多]

重性抑郁障礙（MDD）是一種使人衰弱的精神障礙，在美國約有20000000流行病例。然而不同的抗抑郁藥可用于治療不同的抑郁癥，，約50%的抑郁癥患者的初始治療結果不理想。最近有證據表明，在發(fā)病的幾個(gè)小時(shí)內氯胺酮給藥治療難治性抑郁癥已經(jīng)顯著(zhù)有所改善。勃林格殷格翰公司尋找氯胺酮在人體中反應和持續的抗抑郁作用的機理。 Boehringer Ingelheim Challenge: Understanding the Antidepressant Effect of Ketamine TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $21,000 USD | DEADLINE: 1/15/15 | ACTIVE SOLVERS: 20 | POSTED: 12/15/14 1. The Challenge and qualification for the award Major depressive disorder (MDD) is a debilitating psychiatric disorder with about 20 million prevalent cases in the United States. Various antidepressants are available for treatment of patients suffering from MDD, however, about 50% of MDD patients do not respond adequately to initial treatments. Recent evidence shows that ketamine administered to patients with treatment resistant depression has resulted in marked improvement within hours of treatment. Boehringer Ingelheim (the Seeker) desires a working hypothesis for ketamine’s mechanism of action and sustained antidepressant effect. The submitted solutions will be considered for the award. There will be a guaranteed award for at least one submitted solution. The total payout will be $21,000, with at least one award being no smaller than $12,000 and no award being smaller than $3,000. 2. Additional application for Research Funding In addition to consideration for the award for the submitted Solutions, Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the Solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of this Challenge, and will require the submission of additional information. The decision to fund research will be at the discretion of the Seeker.   [更多]

抑制細胞外神經(jīng)信號的作用可以通過(guò)抑制受體或去除配位體來(lái)產(chǎn)生。我們需要一個(gè)實(shí)例或證據來(lái)證明抑制受體和損耗配體是怎么阻斷信號的，比如可以變構小分子或大分子或競爭性抑制。具體看下面鏈接： https://www.innocentive.com/ar/challenge/9933720 AWARD: $20,000 USD | DEADLINE: 2/25/15 | ACTIVE SOLVERS: 19 | POSTED: 1/26/15 Inhibition of extracellular signaling can occur through an inhibition of a receptor or removal of a ligand. What evidence is there that one method of inhibition is more efficient or efficacious than the other at blocking signaling? The Seeker is specifically looking for well-supported examples of receptor/ligand inhibition where both methods of inhibition exist. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933720 Challenge Overview Inhibition of extracellular neuronal signaling can occur through the inhibition of a receptor or removal of a ligand. What evidence is there (or lack of) that one method of inhibition (inhibition of the receptor versus depletion of the ligand) is more efficient or efficacious than the other at blocking signaling? Inhibition can be allosteric or competitive, small molecule or large molecule. The Seeker is specifically looking for well-supported examples of receptor/ligand inhibition where both methods of inhibition exist. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on February 25, 2015. Late submissions will not be considered.   [更多]

藥物代謝酶的過(guò)程中，肝臟是主要負責將藥物基質(zhì)脂溶性化合物轉化為水溶性代謝物，可以很容易地通過(guò)腎臟排泄的。偶爾，這些代謝產(chǎn)物也會(huì )不恰當地和血蛋白結合，從而導致藥物的不良反應。阿斯利康希望尋找一種定量測定共價(jià)結合細胞蛋白質(zhì)的新方法。具體的鏈接請看下面： https://www.innocentive.com/ar/challenge/9933662 AWARD: $25,000 USD | DEADLINE: 3/16/15 | ACTIVE SOLVERS: 74 | POSTED: 1/16/15 Drug metabolism is the enzymatic process by which the body modifies pharmaceutical substrates. The liver is primarily responsible for reactions which convert lipid-soluble compounds into water-soluble metabolites that can easily be excreted by the kidney. Occasionally, these metabolites exhibit chemically reactivity towards host proteins, leading to inappropriate binding that may result in adverse drug reactions. AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding to cellular proteins. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933662 Challenge Overview When new medicines are introduced to the market, not only does the drug need to have a proven therapeutic benefit, but it also must possess an acceptable safety profile. To this end, drug development focuses on minimizing adverse drug reactions (ADRs) and idiosyncratic drug toxicities. ADRs are a major complication of drug therapy and come as a result of drug accumulation and/or the formation of chemically reactive metabolites (CRMs). Formation of CRMs within a cell poses an undesirable chemical liability and for this reason, AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding of metabolites to cellular proteins. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an   [更多]

腎近端小管是腎單位的一部分(腎臟的功能部件)，是人體高專(zhuān)屬性參與重吸收和排泄各種物質(zhì)（包括鹽和礦物質(zhì)）的器官，鹽和礦物質(zhì)的重吸收對身體是非常重要的，否則會(huì )失去在尿液中。此外，腎近端小管對許多藥物的處理也是至關(guān)重要的，所謂的外源性物質(zhì),來(lái)自外面的身體和環(huán)境(如許多人造物質(zhì),包括潛在的毒素)。然而,沒(méi)有好的體外模型可以描述和模仿腎近端小管的功能。建立腎近端小管一個(gè)有力的模型是非常必要的，特別是在腎近端小管在藥物的相互影響方面有至關(guān)重要的作用，因為它是會(huì )由于藥物毒性和藥物之間的作用而非常容易受到傷害導致腎臟疾病。在體外開(kāi)發(fā)腎近端小管模型的系統可以幫助填補腎臟疾病研究中藥物毒性和藥物處理方面的一些空白。 具體看 https://www.innocentive.com/ar/challenge/9933749 The proximal tubule, a part of the kidney nephron (the functional unit of the kidney), has highly specialized properties to do with the salvage and excretion of various compounds, salts and minerals that are very important to the body and would otherwise be lost in the urine. In addition, the proximal tubule is essential for the handling of many drugs and so-called xenobiotics that come from outside the body and from the environment (e.g., many artificial substances, including potential toxins). However, there are no good human models in vitro that can recapitulate and reproduce the function of the proximal tubule. A robust model for the proximal tubule is needed, especially since the proximal tubule has an essential role in drug clearance, because it is highly susceptible to damage in many kidney diseases, and it is also a target for drug-drug interactions and drug toxicity. Development of a proximal tubule model system in vitro could help to address some of the gaps in laboratory models for the study of kidney disease, toxicity, and drug handling. AstraZeneca is seeking innovative approaches to developing a model system of the proximal tubule in vitro. Ideally, the model should incorporate a self-contained microphysiological unit in which biologically appropriate media, fluid flow, and shear stress can be modulated to reproduce the properties of the proximal tubule in vivo and ultimately recapitulate the structural and cellular conditions necessary for integrated proximal tubular function. This is an ideation challenge and only requires a written solution. Source: InnoCentive Challenge ID:   [更多]

阿斯利康提出需求：在大多數的慢性腎臟疾病的情況下有關(guān)腎小球濾過(guò)屏障功能受損的研究。缺少良好的腎小球體外模型，就不能在細胞學(xué)和病理學(xué)的范疇詳細理解腎小球的功能。 阿斯利康正在尋找方法來(lái)開(kāi)發(fā)一個(gè)腎小球模型系統。理想情況下,體外模型應該包含一個(gè)獨立的微型藥學(xué)單元，有適當的介質(zhì)，流體流動(dòng)和所受壓力?？梢哉{整模擬體內黏膜所需條件屬性，最終建立形成一個(gè)功能腎小球濾過(guò)屏障。 具體看下面內容： https://www.innocentive.com/ar/challenge/9933748The majority of all cases of chronic kidney disease, a key research area within AstraZeneca, originate in the glomerulus when filtration barrier function is compromised. However, a detailed cellular understanding of the functioning and pathology of the glomerulus has been limited by the lack of good in vitro models of glomerular function. AstraZeneca is looking for approaches to develop a glomerular model system. Ideally, the in vitro model should incorporate a self-contained microphysiological unit where biologically appropriate media, fluid flow and shear stress can be modulated to simulate in vivo properties that will ultimately recapitulate the conditions necessary for endothelial and podocyte cell types to form a functional glomerular filtration barrier. This is an ideation challenge and only requires a written solution. Source: InnoCentive Challenge ID: 9933748 Challenge Overview The majority of all cases of chronic kidney disease, a key research area within AstraZeneca, originate in the glomerulus when filtration barrier is compromised. The coordinated efforts of the podocytes and endothelium together with their underlying basement membrane establish the glomerular filtration barrier and injury to these cells can lead to loss of kidney function. There are currently no human in vitro models that mimic a functional or diseased glomerulus. Development of a human glomerular filtration barrier biomimetic system will thus address gaps in in vitro models for simulating human kidney disease, toxicity and DMPK. We are looking for innovative approaches to developing a glomerular model that incorporates a self-contained microphysiological unit, ideally including podocytes, the endothelium, and   [更多]

當藥物引起的胃腸道毒性發(fā)生時(shí)，通過(guò)細胞毒性，抑制細胞增殖，或者藥物對受體和酶的不良影響，損害表現為各種臨床癥狀，包括惡心，嘔吐，潰瘍，和腹瀉。理解這一點(diǎn)的重要性并且減少這些負面效果。阿斯利康公司尋求體外模型，有關(guān)胃腸道毒性起效和恢復的研究。 實(shí)驗論證稿件請于2016年10月26日發(fā)送到： https://www.innocentive.com/ar/challenge/9933828   [更多]

1、calcitonin C 是鮭降鈣素的一個(gè)雜質(zhì)。 2、最好是比較權威的資料或者文獻，在業(yè)內有一定的認可。 3、多少的日用劑量對人體是安全的。   [更多]